Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate ...
The pathophysiology of acute viral diseases is complex. It is characterized by strong inflammatory responses driven by immune cells, leading to tissue damage. Currently available in vitro models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results